Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells

Mutations within the KRAS oncogene are associated with the proliferation of various cancers. Therapeutic approaches for treating cancers with such mutations have focused on targeting the downstream protein effectors of KRAS. However, to date, no approved treatment has targeted the mutated KRAS oncog...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Wookjae, Lee, Joon Ho, Jun, Soyeong, Lee, Ji Hyun, Bang, Duhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082849/
https://www.ncbi.nlm.nih.gov/pubmed/30089886
http://dx.doi.org/10.1038/s41598-018-30205-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082849/
https://www.ncbi.nlm.nih.gov/pubmed/30089886
http://dx.doi.org/10.1038/s41598-018-30205-2

Ejemplares similares